ARGX — ARGENX SE

—
Nasdaq · Health Care · Biotechnology · CIK 1697862 · Belgium
Last close
$947.52
Market Cap
$58.92B
52W High
$1072.75
52W Low
$661.85
ADV30
468,412
Next earnings
2026-10-22

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,721,000,000 1,556,000,000 485,000,000 506,000,000 — — —
Jun 2026 1,515,000,000 1,370,000,000 494,000,000 472,000,000 10,032,000,000 3,584,000,000 1,615,000,000
Mar 2026 1,298,000,000 1,177,000,000 394,000,000 366,000,000 — — —
Dec 2025 1,287,877,000 1,138,190,000 359,557,000 532,950,000 8,682,698,000 3,491,289,000 1,359,606,000

Balance + Analyst (yfinance extras)

Retained Earnings
$558,000,000
Inventory
$371,000,000
Receivables
$1,941,000,000
ST Investments
$1,600,000,000
EBIT TTM
$1,903,122,000
Pretax Income TTM
$1,899,294,000
Interest Exp TTM
$3,828,000
Analysts
23

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,315,468,800
EBITDA
$1,612,902,016
Free Cash Flow
$761,769,024
Enterprise Value
$1,533,905,600,512
Total Cash
$5,184,000,000
Total Debt
$47,000,000
Shares Out
62,187,771
Trailing EPS
$26.21
Book Value
$5.38
ROE
23.6%
ROA
11.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,153,482,000 1,054,615,000 1,292,035,000 8,682,698,000 1,359,606,000 7,323,092,000 685,192,000
Dec 2024 2,190,231,000 -17,844,000 833,040,000 6,202,522,000 704,239,000 5,498,283,000 -82,747,000
Dec 2023 1,226,316,000 -420,638,000 -295,053,000 4,542,458,000 444,951,000 4,097,507,000 -420,327,000
Dec 2022 410,746,000 -723,919,000 -709,594,000 3,134,261,000 320,562,000 2,813,699,000 -862,807,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$34.51

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $920.00 · spot: $941.25 · call volume: 450 · put volume: 639
Expected Move to 2026-12-18: ±$101.86 (10.82%) — implied range $839.39 – $1043.11 · ATM straddle on $940.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MRNA Moderna, Inc. $82.56B $206.80 —
BIIB BIOGEN INC. $37.07B $250.79 —
RVMD Revolution Medicines, Inc. $35.19B $162.69 —
BNTX BioNTech SE $21.32B $84.86 —
NBIX NEUROCRINE BIOSCIENCES INC $16.79B $165.92 —

News headlines (Yahoo Finance, 1h cache)

Cradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenx
2026-11-17 13:00 · Yahoo
Biotech Dealmaker: Early-Stage Platforms And Tools Draw Capital As Full Buyouts Remain On The Sidelines This Week
2026-11-14 00:54 · Yahoo
argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal
2026-11-10 22:15 · Yahoo
Argenx to buy peptide platform in potentially billion-dollar deal
2026-11-09 16:27 · Yahoo
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
2026-11-09 10:04 · Yahoo
Argenx to acquire biotech firm Unnatural Products for $1.15 billion
2026-11-09 08:06 · Yahoo
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
2026-11-09 06:00 · Yahoo
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
2026-11-09 06:00 · Yahoo
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
2026-11-07 15:01 · Yahoo
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
2026-11-16 22:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.